Commentary on 'The DOPPS practice monitor for US dialysis care: Trends through december 2011': Results from year one

American Journal of Kidney Diseases

Volumn 61, Issue 2, 2013, Pages 346-348

  Weiner, Daniel E ^a   Winkelmayer, Wolfgang C ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTIBIOTIC AGENT; CINACALCET; HEMOGLOBIN; IRON; VITAMIN D DERIVATIVE;

BLOOD PRESSURE REGULATION; BLOOD TRANSFUSION; DEATH; DRUG COST; DRUG SAFETY; GLYCEMIC CONTROL; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MEDICARE; NOTE; OUTCOME ASSESSMENT; PATIENT CARE; PROSPECTIVE PAYMENT; UNITED STATES;

EID: 84872302334     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.12.003     Document Type: Editorial

References (22)

1. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease prospective payment system Final rule Fed Regist 75 155 2010 49029 49214
2. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease quality incentive program Final rule Fed Regist 76 3 2011 627 646
3. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease prospective payment system and quality incentive program; ambulance fee schedule; durable medical equipment; and competitive acquisition of certain durable medical equipment prosthetics, orthotics and supplies Final rule Fed Regist 76 218 2011 70228 70316
4. W.C. Winkelmayer, G.M. Chertow The 2011 ESRD prospective payment system: an uncontrolled experiment Am J Kidney Dis 57 4 2011 542 546
5. Centers for Medicare & Medicaid Services Medicare program: changes to the end-stage renal disease prospective payment system transition budget-neutrality adjustment Interim final rule with comment period Fed Regist 76 66 2011 18930 18934
6. D.E. Weiner, W.C. Winkelmayer Commentary on 'The DOPPS Practice Monitor for US dialysis care: trends through August 2011': an ESA confluence Am J Kidney Dis 60 1 2012 165 167
7. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 9 1998 584 590
8. General Accounting Office End stage renal disease: bundling Medicare's payment for drugs with payment for all ESRD services would promote efficiency and clinical flexibility GAO-07-77 http://www.gao.gov/new.items/d0777.pdf November 2006 Accessed November 23, 2009
9. F. Ismail-Beigi, T. Craven, M.A. Banerji Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 9739 2010 419 430
10. H.C. Gerstein, M.E. Miller, S. Genuth Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 9 2011 818 828
11. E. Lacson Jr, W. Wang, B. Zebrowski, R. Wingard, R.M. Hakim Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report Am J Kidney Dis 60 4 2012 591 600
12. S. Wright, D.E. Weiner Oral nutritional supplement use in dialysis patients: full speed ahead? Am J Kidney Dis 60 4 2012 507 509
13. B. Robinson, D. Fuller, D. Zinsser The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system Am J Kidney Dis 57 6 2011 822 831
14. D.S. Fuller, R.L. Pisoni, B.A. Bieber, B.W. Gillespie, B.M. Robinson The DOPPS Practice Monitor for US dialysis care: trends through December 2011 Am J Kidney Dis 61 2 2013 342 346
15. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
16. US Food and Drug Administration FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease http://www.fda.gov/Drugs/DrugSafety/ ucm259639.htm June 24, 2011 Accessed March 16, 2012
17. Centers for Medicare & Medicaid Services Medicare program; changes to the end-stage renal disease prospective payment system for CY 2012, end-stage renal disease Quality Incentive Program for PY 2013 and PY 2014; ambulance fee schedule; and durable medical equipment Fed Regist 76 131 2011 40498 40550
18. Centers for Medicare & Medicaid Services Medicare program; end-stage renal disease prospective payment system, Quality Incentive Program, and bad debt reductions for all Medicare providers Proposed rule Fed Regist 77 2012 40592 41000
19. H.N. Ibrahim, A. Ishani, R.N. Foley, H. Guo, J. Liu, A.J. Collins Temporal trends in red blood transfusion among US dialysis patients, 1992-2005 Am J Kidney Dis 52 6 2008 1115 1121
20. H.N. Ibrahim, M.A. Skeans, Q. Li, A. Ishani, J.J. Snyder Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes Clin Transplant 25 4 2011 653 659
21. A.J. Collins ESRD payment policy changes: the new "bundled" dialysis prospective payment system (PPS) in the United States http://www.usrds.org/2012/pres/USDialysisBundle-impact-NKFCM2012.pdf Accessed July 4, 2012
22. S. Watnick, D.E. Weiner, R. Shaffer, J. Inrig, S. Moe, R. Mehrotra Comparing mandated health care reforms: the Affordable Care Act, accountable care organizations, and the Medicare ESRD program Clin J Am Soc Nephrol 7 9 2012 1535 1543